



### Memorandum of Response

**To:** Danielle Dillard, Regulatory Policy Advocate  
Common Sense Initiative

**From:** Ali Simon, Public and Policy Affairs Liaison  
State of Ohio Board of Pharmacy

**Date:** January 31, 2019

**Re:** Prescriber Drug Compounding (OAC 4729:7-3-01, 4729:7-3-02, 4729:7-3-03, 4729:7-3-04, 4729:7-3-05, 4729:7-3-06, 4729-16-04, 4729-16-09, 4729-16-11, and 4729-16-13)

---

Thank you for your review of the rule package received by the Board of Pharmacy on January 31, 2019.

Since filing the original Business Impact Analysis with the Common Sense Initiative, the rules have been renumbered to reflect stakeholder feedback. The rule package will no longer include 4729:7-1-01. The definition section will now be 4729:7-3-01, as reflected in the Board's initial comment response memo submitted to CSI on December 15, 2018. Based on your approval of the package, the State of Ohio Board of Pharmacy will continue its rule filing process with the Joint Committee on Agency Rule Review (JCARR).

